Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Takara Bio Inc. currently has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. This focused level of activity suggests a precise strategy for protecting biological and pharmaceutical innovations. The 2 pending actions represent the company's current active matters under review by the patent office.
The prosecution is managed by 2 distinct examiners across 2 distinct art units. This 1:1 ratio between actions and examiners indicates that each matter is being reviewed independently by a different person in a different administrative division. This structure ensures that the 2 pending matters are evaluated on their own merits without the influence of a single examiner's perspective.
LARA, CAROLINE MONSERRAT is identified as the busiest examiner, currently managing 1 busiest examiner pending office action. Because this examiner is responsible for only 1 of the 2 total actions, the workload is perfectly balanced. Success in the Biotechnology & Pharmaceuticals sector for these filings will require meeting the distinct expectations of 2 different examiners in 2 separate art units.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LARA, CAROLINE MONSERRAT | 1 | 85.7% | +16.7% |
| SIFFORD, JEFFREY MARK | 1 | 55.1% | +32.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18847384 | EFFICIENT SYSTEM FOR PRODUCING ADENO-ASSOCIATED VIRUS (AAV) VECTOR | LARA, CAROLINE MONSERRAT | — |
| 17767195 | siRNA EXPRESSION VECTOR | SIFFORD, JEFFREY MARK | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18847384 | EFFICIENT SYSTEM FOR PRODUCING ADENO-ASSOCIATED VIRUS (AAV) VECTOR | LARA, CAROLINE MONSERRAT | — |
| 17767195 | siRNA EXPRESSION VECTOR | SIFFORD, JEFFREY MARK | — |
| Art Unit | Apps |
|---|---|
| 1633 | 1 |
| 1671 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18847384 | EFFICIENT SYSTEM FOR PRODUCING ADENO-ASSOCIATED VIRUS (AAV) VECTOR | LARA, CAROLINE MONSERRAT | 1633 | §102§103 | Non-Final OA | — | Pending | Sep 16, 2024 |
| 17767195 | siRNA EXPRESSION VECTOR | SIFFORD, JEFFREY MARK | 1671 | §103§112 | Non-Final OA | — | Pending | Apr 07, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTakara Bio Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Caroline Monserrat Lara has the most, with 1 of Takara Bio Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
